# Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)

Study · id `cardio:ct-nct07308847` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07308847](<https://clinicaltrials.gov/study/NCT07308847>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07308847

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 300 participants.

## Technical summary

Registry record NCT07308847. Allocation not applicable; no masking; primary purpose treatment. Start 2026-01-15 (actual); primary completion 2027-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 300 participants (enrolled count; ClinicalTrials.gov record NCT07308847, source copy `cardio:ctgov-nct07308847-2026-11-06`, retrieved 2026-11-18)
- Started: 2026-01-15 (actual) (ClinicalTrials.gov record NCT07308847, source copy `cardio:ctgov-nct07308847-2026-11-06`, retrieved 2026-11-18)
- Primary completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT07308847, source copy `cardio:ctgov-nct07308847-2026-11-06`, retrieved 2026-11-18)
- Completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT07308847, source copy `cardio:ctgov-nct07308847-2026-11-06`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT07308847, source copy `cardio:ctgov-nct07308847-2026-11-06`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07308847-2026-11-06`, retrieved 2026-11-18)

## The registry's words

- Brief title: Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
- Acronym: Horizon 360
- Condition: Paroxysmal AF
- Intervention (Device): Sphere-360 Pulsed Field Ablation Catheter with the Affera Mapping and Ablation System
- Lead sponsor: Medtronic Cardiac Ablation Solutions
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Medtronic Cardiac Ablation Solutions (`cardio:org-medtronic-cardiac-ablation-solutions`)

## Provenance

Content hash: 73fec65211b1b228e64762c668722100b41eb837ae96a3bf9e2568e798c8cb15
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
